Studying DNA in Tumor Tissue Samples From Patients With Localized or Metastatic Osteosarcoma
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is looking at DNA in tumor tissue samples from patients with localized or metastatic osteosarcoma.
Genetic: DNA analysis
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: gene rearrangement analysis
Genetic: mutation analysis
Other: laboratory biomarker analysis
|Official Title:||Genomic Study of Metastatic Osteosarcoma Using Next-Generation Sequencing Technology|
- Genomic expression profile in osteosarcoma tumor samples using transcriptome sequencing [ Designated as safety issue: No ]
- Identification of activating and loss of function mutations and gene rearrangement using transcriptome sequencing [ Designated as safety issue: No ]
- Mutations associated with outcome [ Designated as safety issue: No ]
- Mutations also found in germ line DNA that predispose the patient to osteosarcoma [ Designated as safety issue: No ]
|Study Start Date:||January 2010|
|Primary Completion Date:||September 2011 (Final data collection date for primary outcome measure)|
- Determine the genomic expression profile in tumor tissue samples from patients with localized or metastatic osteosarcoma using transcriptome sequencing.
- Identify activating and loss of function mutations and gene rearrangement in these tumor tissue samples using transcriptome sequencing.
- Identify candidate genes that are important in osteosarcoma and tumorigenesis using genome partition strategies for genomic DNA sequencing.
- Identify which mutations are associated with outcome.
- Establish which mutations are also found in germ line DNA that predispose the patient to osteosarcoma.
OUTLINE: DNA and RNA from banked tumor tissue samples and DNA from paired blood samples are analyzed in sequencing studies using next-generation sequencing technology. The sequencing data from these tumor samples are matched to the Human RefSeq (for transcriptome sequencing) and normal human genome in the public databases and to the patient's germ line sequence to identify constitutional and somatic mutations.
Clinical information that is associated with each sample (i.e., age, tumor site, size, primary metastases, response to chemotherapy, surgical remission, follow-up time, and treatment protocol) is also collected, if available.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01062438
|Principal Investigator:||Javed Khan, MD||NCI - Oncogenomics Section|